Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics (TRDA) with an Early-Stage Biotech designation, saying the company’s Endosomal Escape Vehicle platform is differentiated from other delivery peptide approaches. It sees “best-in-class potential.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
- Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
- Entrada Therapeutics Reports Q2 2025 Financial Results
- Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
- Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)